TransMedics Group, Inc. (NASDAQ:TMDX) Given Consensus Rating of “Moderate Buy” by Analysts

TransMedics Group, Inc. (NASDAQ:TMDX) has been given a consensus recommendation of “Moderate Buy” by the eight analysts that are presently covering the company, Marketbeat.com reports. One investment analyst has rated the stock with a hold rating and seven have assigned a buy rating to the company. The average 1-year target price among brokerages that have issued ratings on the stock in the last year is $166.88.

Several research firms have recently issued reports on TMDX. Morgan Stanley boosted their price objective on shares of TransMedics Group from $104.00 to $145.00 and gave the stock an “equal weight” rating in a report on Monday, July 15th. TD Cowen boosted their price objective on shares of TransMedics Group from $130.00 to $175.00 and gave the stock a “buy” rating in a report on Friday, June 7th. Piper Sandler boosted their price objective on shares of TransMedics Group from $170.00 to $180.00 and gave the stock an “overweight” rating in a report on Thursday. JPMorgan Chase & Co. lifted their target price on shares of TransMedics Group from $105.00 to $127.00 and gave the company an “overweight” rating in a research report on Wednesday, May 1st. Finally, Canaccord Genuity Group lifted their target price on shares of TransMedics Group from $117.00 to $169.00 and gave the company a “buy” rating in a research report on Thursday.

Insider Buying and Selling at TransMedics Group

In other news, CEO Waleed H. Hassanein sold 8,625 shares of the company’s stock in a transaction that occurred on Monday, July 15th. The shares were sold at an average price of $145.17, for a total transaction of $1,252,091.25. Following the transaction, the chief executive officer now directly owns 61,643 shares in the company, valued at $8,948,714.31. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. In related news, CEO Waleed H. Hassanein sold 8,625 shares of the business’s stock in a transaction that occurred on Monday, July 15th. The shares were sold at an average price of $145.17, for a total transaction of $1,252,091.25. Following the completion of the sale, the chief executive officer now directly owns 61,643 shares of the company’s stock, valued at $8,948,714.31. The transaction was disclosed in a legal filing with the SEC, which is available at this link. Also, Director David Weill sold 1,193 shares of the company’s stock in a transaction that occurred on Wednesday, May 29th. The shares were sold at an average price of $141.65, for a total transaction of $168,988.45. Following the completion of the sale, the director now directly owns 10,732 shares of the company’s stock, valued at approximately $1,520,187.80. The disclosure for this sale can be found here. Insiders have sold a total of 101,342 shares of company stock worth $13,642,015 over the last ninety days. Corporate insiders own 7.00% of the company’s stock.

Institutional Investors Weigh In On TransMedics Group

Large investors have recently made changes to their positions in the stock. Vanguard Group Inc. increased its position in shares of TransMedics Group by 1.7% during the third quarter. Vanguard Group Inc. now owns 1,814,442 shares of the company’s stock worth $99,341,000 after acquiring an additional 29,798 shares in the last quarter. Goldman Sachs Group Inc. boosted its holdings in TransMedics Group by 10.9% during the fourth quarter. Goldman Sachs Group Inc. now owns 397,283 shares of the company’s stock worth $31,358,000 after purchasing an additional 38,951 shares during the last quarter. Moody Aldrich Partners LLC boosted its holdings in TransMedics Group by 110.3% during the fourth quarter. Moody Aldrich Partners LLC now owns 46,312 shares of the company’s stock worth $3,655,000 after purchasing an additional 24,290 shares during the last quarter. Alpha DNA Investment Management LLC acquired a new position in TransMedics Group during the fourth quarter worth $500,000. Finally, Russell Investments Group Ltd. boosted its holdings in TransMedics Group by 337,462.5% during the first quarter. Russell Investments Group Ltd. now owns 27,005 shares of the company’s stock worth $1,997,000 after purchasing an additional 26,997 shares during the last quarter. Institutional investors own 99.67% of the company’s stock.

TransMedics Group Stock Performance

Shares of TMDX opened at $150.10 on Friday. The company has a market capitalization of $4.94 billion, a PE ratio of -441.47 and a beta of 1.99. TransMedics Group has a one year low of $36.42 and a one year high of $171.98. The company has a debt-to-equity ratio of 3.18, a current ratio of 9.72 and a quick ratio of 8.76. The company’s fifty day moving average price is $144.02 and its 200 day moving average price is $111.05.

TransMedics Group (NASDAQ:TMDX) last posted its quarterly earnings data on Wednesday, July 31st. The company reported $0.35 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.21 by $0.14. TransMedics Group had a net margin of 0.84% and a return on equity of 17.37%. The company had revenue of $114.30 million for the quarter, compared to the consensus estimate of $98.84 million. During the same quarter in the previous year, the firm posted ($0.03) EPS. The business’s revenue was up 117.7% compared to the same quarter last year. As a group, analysts expect that TransMedics Group will post 0.81 earnings per share for the current year.

TransMedics Group Company Profile

TransMedics Group, Inc, a commercial-stage medical technology company, engages in transforming organ transplant therapy for end-stage organ failure patients in the United States and internationally. The company offers Organ Care System (OCS), a portable organ perfusion, optimization, and monitoring system that utilizes its proprietary and customized technology to replicate near-physiologic conditions for donor organs outside of the human body.